Solutions
Online Inquiry
Global Services. (Creative Biolabs Authorized)

Blastoma Specific CAR Construction Service

Online Inquiry
Background Service Workflow Highlights FAQs Contact Products

Struggling with tough, solid tumors, worrying about side effects, or finding your CAR-T cells just aren't sticking around? Don't sweat it! Our blastoma-specific CAR construction service helps you expedite the process and deliver safer, more effective treatments. We utilize advanced CAR engineering and rigorous testing, providing comprehensive, customized solutions to address blastoma challenges from start to finish.

Introduction

Blastoma is a cancer arising from embryonic tissue, more common in children than adults. Based on tumor location, subtypes include medulloblastoma, hepatoblastoma, nephroblastoma, pleuropulmonary blastoma, retinoblastoma, neuroblastoma, and osteoblastoma. Symptoms vary, and treatment often involves surgery, radiation, and chemotherapy, which may cause long-term side effects. Adoptive cell therapy targeting blastoma-specific antigens offers a promising alternative. The chimeric antigen receptor (CAR)-modified T or NK cells have already entered clinical trials for blastoma treatment.

Fig.1 Design of the single-chain variable fragment as a key part in CAR-T cells. (OA Literature)Fig.1 Design of a single-chain variable fragment in CAR-T cells.1

Blastoma-Specific CAR Construction Service at Creative Biolabs

Creative Biolabs' blastoma-specific CAR construction service delivers bespoke CAR constructs and expertly engineered T cells, providing you with critical solutions to advance your oncology projects. We address key challenges in solid tumor targeting, offering meticulously designed CARs with enhanced specificity and functionality. Our service provides comprehensive preclinical data, empowering you to make informed decisions and accelerate your therapeutic candidates toward clinical translation.

Creative Biolabs has many years of experience in CARs construction for targeting blastoma-specific antigens. We can provide highly customized and best-in-class CAR products according to our special and strict requirements.

  • Antibody Sequence Screening and single chain variable fragment (scFv) Construction: We acquire scFv sequences either via de novo antibody development or through public databases and patent literature.
  • CAR Structure Design: We assemble CAR constructs by combining a signal peptide, the optimized scFv, a flexible hinge, a transmembrane domain, and intracellular signaling modules.

Service Process

The workflow of blastoma-specific CAR construction service. (Creative Biolabs Original)

Key Advantages

  • Cutting-Edge Platforms: Access to state-of-the-art facilities and proprietary platforms for CAR engineering, viral vector production, and advanced in vitro and in vivo validation.
  • Rigorous Quality Control: Our multi-stage QC process ensures high CAR expression, potent cytotoxicity, and optimal cell viability, providing you with reliable and consistent results.
  • Commitment to Safety and Efficacy: Our designs prioritize both potent anti-tumor activity and robust safety profiles, incorporating advanced features like conditional suicide genes and dual-receptor systems.

FAQs

Q1: What types of blastoma antigens can your service target?

A: We can target a wide range of blastoma-specific antigens, including established markers and novel neo-antigens identified through advanced genomic analysis. Our team performs thorough validation to ensure optimal specificity and minimal off-target expression, crucial for solid tumor applications.

Q2: How do you ensure the safety of the constructed CARs for solid tumor applications?

A: Safety is paramount in our CAR design. We incorporate advanced safety features such as conditional suicide genes for rapid elimination of CAR-T cells in case of severe toxicity, and regulatable CAR expression systems for dose-dependent control. For enhanced precision, we also offer dual receptor CAR designs that require two distinct antigen recognitions for full activation, significantly reducing the risk of off-target effects.

Q3: Can you work with patient-derived T cells or only cell lines for CAR engineering?

A3: Our service is highly flexible and can accommodate various starting materials. We routinely work with both patient-derived peripheral blood mononuclear cells (PBMCs) or splenocytes for preclinical models, as well as established T cell lines, depending on your specific project requirements and the stage of your research.

Why Choose Us?

Creative Biolabs is dedicated to accelerating the development of life-changing immunotherapies. Our blastoma-specific CAR construction service stands as a testament to our commitment to precision, quality, and innovation in the fight against aggressive solid tumors. By leveraging our deep expertise and state-of-the-art platforms, we empower our partners to achieve breakthroughs faster and more efficiently.

Customer Reviews

"Using Creative Biolabs' blastoma-specific CAR construction service in our glioblastoma research has significantly improved the specificity of our CAR constructs, reducing concerns about off-target effects compared to previous general approaches. Their dual receptor system design was particularly impactful." – 2024, An Sh

"The end-to-end workflow provided by Creative Biolabs, from scFv development to comprehensive QC, greatly facilitated our neuroblastoma CAR-T project. The detailed protocols and consistent results saved us considerable time and resources." – 2023, La Mr

How to Contact Us

Ready to advance your blastoma therapy project? Our expert team is here to provide detailed information and discuss how our tailored solutions can meet your specific needs.

For more information or to discuss your specific project, please reach out to our team.

Products against Blastoma-specific antigens

Please note: If you do not find the wanted antigen, please feel free to contact us. Our highly skilled staff is very glad to help you.

Associated malignancy Target antigen Receptor type Product
Glioblastoma IL13RA2 scFv-CD28-OX40-CD3ζ CAR-T-3-M401-2XZ
EGFRvIII scFv-CD28-41BB-CD3ζ CAR-LC056
IL13Rα2 scFv-CD28-41BB-CD3ζ CAR-LC236
CSPG4 scFv-CD28-CD3ζ CAR-MZ116
IL13Rα2 IL13 mutein E13K-CD28-CD3ζ CAR-MZ238
Hepatoblastoma GPC3 scFv-CD28-OX40-CD3ζ CAR-T-3-L342-2XZ
HBV scFv-CD28-41BB-CD3ζ CAR-T-3-M319-2BZ
ErbB2 VHH-CD28-OX40-CD3ζ CAR-T-3-M550-2XZ
Glypican-3 (GPC3) scFv-CD28-41BB-CD3ζ CAR-LC180
Neuroblastoma GD2 scFv-CD28-41BB-CD3ζ CAR-NK-3-M330-2BZ
CD171 scFv-CD28-41BB-CD3ζ CAR-T-3-M307-2BZ

Reference

  1. Jayaraman, Jayapriya et al. "CAR-T design: Elements and their synergistic function." EBioMedicine vol. 58 (2020): 102931. https://doi.org/10.1016/j.ebiom.2020.102931. Distributed under Open Access License CC BY 4.0, without modification.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Key Updates
Newsletter. (Creative Biolabs Authorized) NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution. (Creative Biolabs Authorized) NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
Novel Solution. (Creative Biolabs Authorized) NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
New Technology. (Creative Biolabs Authorized) NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.